Kate Cassidy expects that AI and developing deals will create a demand for strong life sciences litigators
Pravin Anand and Vaishali Mittal of Anand & Anand explain how they helped Swiss pharma company Vifor secure a landmark win against generic companies in India
Principals Martina Hufnal and Todd Garcia will lead the firm’s new life sciences industry group, which is set to 'formalise' certain practices
US pharma lawyers spoke to Managing IP about their top concerns and reveal how external counsel can help
The UPC’s Court of Appeal said Mathys & Squire and Bristows hadn’t proved a 'direct and present interest' in Ocado v Autostore
The latest copy of a draft pandemic treaty shows the US and its allies are digging in over developing countries’ request for mandatory tech transfer
The latest working draft, seen by Managing IP, features competing visions of a pandemic IP regime advanced by the US and developing nations
The EPO declined to attend the latest meeting organised by the Industry Patent Quality Charter, a group that has called on the office to grant higher-quality patents
The Munich local division was wrong to side with Amgen over the drugmaker’s failure to upload annexes to its infringement suit on time, the appeal court ruled
Judge Matthias Zigann said the panel wasn’t convinced that NanoString had infringed the 10x Genomics patent
The Ministry of Health has passed a resolution declaring public interest in the drug dolutegravir
Johnson & Johnson won’t enforce patents for bedaquiline after months of public scrutiny and new licences for generics
Sponsored
Sponsored
-
Sponsored by Wanhuida Intellectual PropertyJianhui Li and Honghui Hu of Wanhuida Intellectual Property discuss the antitrust scrutiny of China’s Supreme People’s Court in a patent infringement appeal concerning reverse payment settlement agreement
-
Sponsored by Purplevine IPXiaojuan Yu of Purplevine IP Group discusses the medical device industry in China and considers why changes to the law are welcomed
-
Sponsored by FB RiceLee Miles of FB Rice discusses Australia’s patent box scheme which is set to introduce the agricultural and low emissions technology sectors
-
Sponsored by Gün and PartnersBarış Kalaycı and Direnç Bada of Gün and Partners discuss an IP case that led to the discovery, and removal, of fake fire-resistant glass from hospitals in Turkey
-
Sponsored by Wanhuida Intellectual PropertyThe China Patent Office upheld the validity of the patent over the antihistamine desloratadine citrate disodium, as Yue Guan from Wanhuida Intellectual Property explains
-
Sponsored by Remfry & SagarShukadev Khuraijam and Ankush Verma of Remfry & Sagar discuss pre-grant straw man oppositions in India and the impact of a recent decision of the Bombay High Court
-
Sponsored by LexOrbisManisha Singh and Pradeep Kumar Kamal of LexOrbis explain how India has adopted a unique solution to protecting the rights of plant breeders and farmers
-
Sponsored by Gün and PartnersAysel Korkmaz Yatkın and Fatma Sevde Tan of Gün and Partners discuss a welcome decision that reinforces patent owners’ right to information about pharmaceutical licensing applications in Turkey
-
Sponsored by Wanhuida Intellectual PropertyXiaohui Wu, Yuming Wang and Jianhui Li of Wanhuida Intellectual Property discuss the Supreme People’s Court’s first decision in parallel civil and administrative proceedings involving a chiral drug patent
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
The Biden administration has published draft guidance that could let the government override exclusive patent licences where drug prices are deemed too high
Mike Renaud, head of the IP division at Mintz, explains his business strategy and how the firm justifies charging higher rates
Counsel could be more hesitant to recommend means-plus-function claims for life sciences patents if the Federal Circuit rules against Xencor
Interviews; Exclusives
Interviews; Exclusives
Fatima Hassan, director of Health Justice Initiative, says IP office actions can yield major wins for patients and activists
Each week Managing IP speaks to a different IP lawyer about their life and career
Counsel explain how they helped Eli Lilly overturn a damages award related to its migraine drug and why Supreme Court guidance proved useful
Samantak Ghosh, senior IP counsel at Gilead, talks about his pivot from research to law, the rise of biologics, and his pro bono work
Each week Managing IP speaks to a different IP lawyer about their life and career
Each week Managing IP speaks to a different IP lawyer about their life and career
-
Weekly take: IP-trade demands will fail future generations
The bedaquiline case highlights why tools such as India’s pre-grant opposition mechanism are so important -
Weekly take: No harm in senators exploring patent alternatives
A proposed study into delinkage may not amount to much, and must be backed by strong evidence, but it can’t hurt to look into the issue -
Opinion: Indian domestic policy must match WTO stand on IP waivers
India has been both urging for vaccine waivers before the WTO and refusing compulsory licensing in the country, but it’s not helping anyone